Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Liver Diseases × Lymphoid × Clear all

Phase

Status

Completed 4 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5 Lymphoid 1

Conditions

Lymphoma 331 Lymphoma, Non-Hodgkin 308 Leukemia, Lymphocytic, Chronic, B-Cell 286 Precursor Cell Lymphoblastic Leukemia-Lymphoma 262 Lymphoma, Large B-Cell, Diffuse 213 Lymphoma, Follicular 210 Leukemia 181 Hodgkin Disease 148 Lymphoma, Mantle-Cell 145 Leukemia, Myeloid, Acute 144 Multiple Myeloma 120 Myelodysplastic Syndromes 118 Recurrence 111 Burkitt Lymphoma 111 Lymphoma, B-Cell, Marginal Zone 108 Lymphoma, T-Cell, Cutaneous 82 Mycosis Fungoides 74 Neoplasms 70 Lymphoma, B-Cell 69 Waldenstrom Macroglobulinemia 66 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 64 Sezary Syndrome 63 Lymphoma, Large-Cell, Immunoblastic 60 Neoplasms, Plasma Cell 50 Myeloproliferative Disorders 50 Lymphoma, Large-Cell, Anaplastic 48 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 47 Primary Myelofibrosis 43 Blast Crisis 41 Hematologic Neoplasms 39

Interventions

ledipasvir, sofosbuvir drug combination 1 Sofosbuvir 1 Ribavirin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02717949 2019-01-08

Optimal

University of Texas Southwestern Medical Center

Phase 4 Terminated

Hepatitis C, Liver Diseases, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡